Photo from Elad Sharon/X
Jul 28, 2024, 14:38
Elad Sharon: Contribution of effect is an under appreciated and essential part of drug development
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared a post by FDA Oncology on X:
“Absolutely, the right message to send… Contribution of effect is an under appreciated and essential part of drug development.
I don’t even think the perioperative period is the most essential place to start… but you gotta start somewhere.”
Quoting FDA Oncology’s post:
“Oncologic Drugs Advisory Committee votes 11 to 0 in favor of FDA requiring that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment of contribution of treatment phase.”
Link to video.
Source: Elad Sharon/X and FDA Oncology/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19